The global swine respiratory diseases treatment market is poised for significant growth, with projections indicating a valuation of USD 1,978.1 million by the end of 2022. This growth trajectory is expected to continue, with a compound annual growth rate (CAGR) of 6.3% from 2022 to 2032, ultimately reaching an estimated USD 3,649.5 million by the end of the forecast period.
The driving force behind this market expansion can be attributed to the increasing prevalence of respiratory diseases in swine populations, alongside a growing awareness of the need for effective treatment options. Among the various causative agents of swine respiratory diseases, Mycoplasma has emerged as the leading contributor, accounting for approximately 35.2% of the market share in 2021. This significant share highlights the critical need for targeted treatment solutions aimed at combating this prevalent pathogen.
The market’s growth is further supported by advancements in veterinary medicine, innovative treatment methodologies, and the rising emphasis on livestock health and productivity. As farmers and livestock producers become more aware of the economic implications of respiratory diseases, investment in effective treatment options is expected to rise, fueling overall market development.
In conclusion, the global swine respiratory diseases treatment market is on a robust growth path, driven by increasing disease prevalence, rising awareness, and advancements in veterinary healthcare. Stakeholders in the industry are encouraged to leverage this momentum to enhance their product offerings and meet the growing demand for effective treatment solutions.
In a significant development, Mycoplasma has emerged as the market leader in the causative agent section, commanding a substantial 35.2% share of the Swine Respiratory Diseases Treatment industry in 2021.
Swine respiratory infections fall into two distinct categories, classified by the scale and duration of the observed conditions. The first category encompasses infections that affect a substantial number of pigs, posing a potential threat, yet exhibiting a brief duration. On the other hand, the second category comprises diseases that affect a large swine population over an extended period.
PRRS (porcine reproductive and respiratory syndrome), the most common respiratory disease in pigs, is treated with drugs and immunizations that aid in the treatment or prevention of swine respiratory infections. Medication is used to treat swine respiratory disorders in a variety of ways, including injections and in-feed inclusions. Vaccination is a biological tool used to boost disease immunity. Live, attenuated vaccines and dead, inactivated vaccines are the two major types of immunizations used to prevent swine respiratory diseases.
Global Swine Respiratory Diseases Treatment Industry: Segmental Highlights
The market is segmented on the basis of the causative agent, treatment type, route of administration, distribution channel, and region.
- The United States dominates the North American swine respiratory disease treatment market, with a total share of around 52.9% in 2021. It is predicted to continue growing at the same rate during the projection period.
- In 2021, Canada owned around 47.1% of the North American Swine Respiratory Diseases Treatment industry, and it is predicted to develop at a profitable CAGR of 6.7% during the forecast period.
- During the projected period, Germany is expected to demonstrate a CAGR of roughly 5.8% in the European swine Respiratory Diseases Treatment market.
- Causative agents based on Mycoplasma are predicted to expand rapidly, with a CAGR of 6.1% by the end of the projection period.
- By the end of the projection period, the pharmaceuticals segment is predicted to rise rapidly at a CAGR of 6.1%.
- By the end of the forecast period, the oral route of administration is predicted to rise at a CAGR of 6.3%.
Global Swine Respiratory Diseases Treatment Industry: Dynamics
The market forecast for various segments is based on the factors that are impacting the global market. According to Future Market Insights analysis, the market is driven by an increase in the rate of diseases such as PRRS (Porcine reproductive and respiratory syndrome), the high demand of pork, and increase in the use of vaccines that are given to pigs in order to produce disease free pork.
However, there are a few factors prevailing in the market that may have a negative impact on the market such as stringent regulation by FDA to limit the use of antibiotics for farm animals and also lack of awareness in many countries where the pig farm owners are unaware of the diseases and treatment processes.
Global Swine Respiratory Diseases Treatment Industry: Competitive Analysis
This comprehensive research report includes brief profiles of various major companies operating in the global market such as Zoetis, Bayer AG, Boehringer Ingelheim GmbH, Elanco Animal Health (Sub. Eli Lilly), Virbac, Norbrook, Ceva Santé Animale, Intervet Inc., (Sub. Merck & Co. Inc.), Vetoquin.
Segmentation of the Global Swine Respiratory Diseases Treatment Industry
The segmentation of the global Swine Respiratory Diseases Treatment industry helps readers simplify the market study and understanding, by dividing the market into different segments on the basis of various parameters. The report provides an individual analysis of each and every segment, thus covering every part of the market.
By Causative Agent
- Virus
- Mycoplasma
- Bacteria
- Others
By Treatment Type
- Drugs
- Antibiotic
- Others
- Vaccines
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies
- Others
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube